title: Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
abstract: Fas/APO-1 (CD95) is a cell surface receptor which mediates apoptosis when ligated by specific antibodies or by its recently cloned natural ligand, FasL. We have studied the cytotoxic potential of FasL in vivo using Fas/APO-1-expressing Yac-1 cells as targets. Supernatant harvested from Neuro-2a cells transfected with the murine FasL cDNA contains FasL and transduces a potent apoptotic signal to Yac-1 cells in vitro. Specificity of FasL-mediated cytotoxicity was confirmed by competition assays using soluble Fas or anti-Fas/APO-1 F(ab')2 fragments which specifically interfere with FasL-Fas/APO-1 interactions. Intraperitoneal injection of FasL-containing supernatant efficiently killed Yac-1 target cells which had been implanted in capsules into the peritoneal cavity of mice. Analysis of the target cells revealed DNA fragmentation and nuclear changes typical of apoptosis. As previously shown, intraperitoneal injection of anti-Fas/APO-1 antibodies caused liver failure (Ogasawara, J., Watanabe, F.R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T. and Nagata, S., Nature 1993. 364:806) and was observed at doses which did not reduce Yac-1 cell viability. In contrast, FasL did not induce histopathology in the liver when applied intraperitoneally at doses cytotoxic for Yac-1 cells. However, intravenous administration of FasL induced lethal liver hemorrhages and hepatocyte apoptosis. Thus, locally applied FasL kills tumor cells very efficiently without systemic toxicity and may therefore represent a candidate for local tumor treatment.
authors.affiliation: Department of Internal Medicine, University Hospital, Zürich, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Rensing-Ehl
authors.forename: K
authors.initials: K
authors.lastname: Frei
authors.forename: R
authors.initials: R
authors.lastname: Flury
authors.forename: B
authors.initials: B
authors.lastname: Matiba
authors.forename: S M
authors.initials: SM
authors.lastname: Mariani
authors.forename: M
authors.initials: M
authors.lastname: Weller
authors.forename: P
authors.initials: P
authors.lastname: Aebischer
authors.forename: P H
authors.initials: PH
authors.lastname: Krammer
authors.forename: A
authors.initials: A
authors.lastname: Fontana
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D000954:Antigens, Surface / Q000276:immunology* / Q000502:physiology / Q000633:toxicity*; D017209:Apoptosis / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D053222:Fas Ligand Protein; D005260:Female; D008297:Male; D008562:Membrane Glycoproteins / Q000008:administration & dosage / Q000502:physiology*; D051379:Mice; D008805:Mice, Inbred A; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D014162:Transfection; D014407:Tumor Cells, Cultured; D019014:fas Receptor
chemical_list: D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008562:Membrane Glycoproteins; D019014:fas Receptor